NEWARK, N.J., July 29 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a chemical technology-based Life Science company announced today that CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania will appear on WVOX AM's "In Focus" radio show on Wednesday July 29, 2009 at 6:00PM.
The radio broadcast may be accessed via the Internet at www.wvox.com/shows.asp.
About Dr. Dan Miller
Dr. Miller is a retired school and college educator and administrator is the Host & Executive Producer of IN FOCUS With Dr. Dan & Friends, one of WVOX's newest popular weekly informative talk shows that promises to educate, inform and entertain its listeners with interesting weekly guests discussing current issues in Health, Education, Business, Politics, Sports and Entertainment
About WVOX: Vox Populi. "The Voice of Westchester."
WVOX is a broadly-based regional community station for residents of suburban Westchester County the Bronx, Queens and the North Shore or Long Island. Emphasis on the heavily-populated cities of Westchester's Southern tier and affluent villages of Long Island
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. BioNeutral has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.
More information about the Company may be found at www.bioneutralgroup.com.
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how BioNeutral's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the BioNeutral's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.
BioNeutral Group Inc. Stephen J. Browand, President and CEO email@example.com Investor Relations Aimee Boutcher 973 239-2878 firstname.lastname@example.org
|SOURCE BioNeutral Group, Inc.|
Copyright©2009 PR Newswire.
All rights reserved